Tessera
Folgen

Peter Hall

@peterhall001.bsky.social

Breast Oncologist and Professor of Cancer Informatics, Edinburgh | Health Economics | Real World Evidence | https://cancer-data.ecrc.ed.ac.uk/

17 Posts219 Follower160 Folgt
Peter Hall@peterhall001.bsky.social · 11mo ago

Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial - The Lancet www.thelancet.com/journals/lan...

Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised ...

The addition of adjuvant chemotherapy to hormonotherapy conferred no survival benefit in women aged 70 years and above with a GGI high-risk oestrogen receptor-positive HER2-negative breast cancer, and...

thelancet.com

Darren Dahly@statsepi.bsky.social · 12mo ago

Target trial emulation is an important, useful idea, but we must remain careful to not allow novices to think it's a magical shortcut to causal inference. Nor can we lose sight of the *main* thing that separates randomized from non-randomized studies.

POTENTIAL RISKS OF TARGET TRIAL TERMINOLOGY There are risks that the term target trial emulation (TTE) might mislead readers without methodological training. We believe some readers may assume TTE represents a distinct form of observational study design, rather than a framework to help researchers identify and avoid self-inflicted errors in observational studies. We are particularly concerned that claims to have emulated an RCT will be mistaken for a claim to have successfully emulated an RCT. The latter statement implies that the inference is of a comparable standard to a well-conducted RCT. To be certain, the TTE framework (2), used correctly, will help investigators specify estimands, and sidestep avoidable selection bias, but we are probably more pessimistic than Schwarze et al. (1) about the ability of ‘‘advanced methods’’ to address the threat of other sources of bias. However, the difference in how randomization accounts for confounding vs. ‘‘advanced methods’’ like covariate adjustment, weighting, etc. is a difference in kind, not in degree. This is because randomization is guaranteed to eliminate confounding for some key estimands, and to do so in a manner that predominantly rests on our trust in a potentially verifiable randomization process. In contrast, acting on the effect estimate returned from an NRSI requires us to trust in the decisions and competence of the investigator, and even then, no guarantee is possible, even in relatively simple sets of relationships among a small set of potential covariates. This distinction will be obvious to methodological experts, but they only constitute a small proportion of researchers and research-consumers
medRxivpreprint@medrxivpreprint.bsky.social · 2y ago

Vaginal estrogen therapy initiation after breast cancer and oncological outcomes: a nationwide population-based target trial emulation. https://www.medrxiv.org/content/10.1101/2024.10.23.24315966v1

Vaginal estrogen therapy initiation after breast cancer and oncological outcomes: a nationwide population-based target trial emulation. https://www.medrxiv.org/content/10.1101/2024.10.23.24315966v1

Background: Genitourinary syndrome of menopause (GSM) frequently occurs after breast cancer (BC), le

medrxiv.org

Cancer Research UK@cancerresearchuk.org · 2y ago

Together with the NIHR (National Institute for Health and Care Research), the EPSRC, Health Data Research UK (HDR UK) and ADR UK (Administrative Data Research UK), we’re announcing a £10m programme which will help identify individual cancer risk 🙌 Read more 👉 cruk.ink/42q0aaY

£10m funding for new programme to help identify individual cancer risk - Cancer Research UK - Cancer News

Today, Cancer Research UK, the NIHR and the EPSRC are announcing £10 million to create the Cancer Data-Driven Detection programme

cruk.ink

Karin Purshouse@karinpurshouse.bsky.social · 2y ago

So happy to share the latest study from NOTCH led by Dr Karen Mactier from @NHS_Lothian @UofGlasgow, looking at UK-wide practice in managing a rare cancer, uterine sarcoma 👇👇👇 pubmed.ncbi.nlm.nih.gov/39725428/

TOURISM study (Treatment Outcomes in UteRIne SarcoMa): a 10-year retrospective evaluation of practice in the UK - PubMed

Our data highlight the diversity in patient management in uterine sarcoma and a marked survival advantage for patients diagnosed with stage I disease. These data highlight the importance of a multidis...

pubmed.ncbi.nlm.nih.gov

Katie Spencer@katiespencer.bsky.social · 2y ago

Are you a health economist, epidemiologist or data scientist with experience using routine healthcare data? Interested in equity in cancer care? Come and join this exciting @nihr.bsky.social funded project! Work with a range of stakeholders and build your skills. jobs.leeds.ac.uk/Vacancy.aspx...

Job Opportunity at University of Leeds: Research Fellow

Are you an ambitious researcher looking for your next challenge? Do you have a background in economics, econometrics, statistics, epidemiology or health data science? Are you interested in working wit...

jobs.leeds.ac.uk

Peter Hall@peterhall001.bsky.social · 2y ago

#SABCS24 FDA session highlighting need to consider Minimum Effictive Dose, not just Maximum Tolerated Dose. Reminds me of the GO2 trial in gastric ca last decade. Breast cancer drug development catching up? jamanetwork.com/journals/jam...

Efficacy of Reduced-Intensity Chemotherapy Among Older and Frail Patients With Advanced Gastroesophageal Cancer

This randomized clinical trial assesses the efficacy of reduced-intensity chemotherapy for patient quality of life and cancer control in the treatment of older and/or frail patients.

jamanetwork.com

Peter Hall@peterhall001.bsky.social · 2y ago

Very good to see more de-escalation trials publishing in HER2 positive early breast cancer. Here the HELEN-006 trial. www.thelancet.com/journals/lan...

De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006)...

These findings might suggest a potential advantage of nab-paclitaxel combined with trastuzumab and pertuzumab compared with the standard regimen in neoadjuvant therapy for patients with HER2-positive ...

thelancet.com

Kristoffer Stewart@journal-kristoffer.bsky.social · 2y ago

📣 Check out this recent study: UK national observational cohort study investigating Tolerance of Anti-cancer Systemic Therapy in the Elderly: the TOASTIE study From @drmarkbaxter.bsky.social and colleagues: bmjoncology.bmj.com/content/3/1/... #cancer #chemotherapy

UK national observational cohort study investigating Tolerance of Anti-cancer Systemic Therapy in the Elderly: the TOASTIE study

Objective The Cancer and Aging Research Group (CARG) score was developed to predict severe chemotherapy-induced toxicity risk in older adults; validation study results have varied. The Tolerance of An...

bmjoncology.bmj.com

Peter Hall@peterhall001.bsky.social · 2y ago

This is how we should be doing Oncology trials - the Dutch SONIA trial looking at treatment sequencing of CDK 4/6 inhibitors in advanced breast cancer. A self funding efficiency trial! #oncsky www.nature.com/articles/s41...

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer - Nature

The phase 3 SONIA trial challenges the benefits of using cyclin-dependent kinase 4 and 6 inhibitors as a first-line compared with second-line treatment.

nature.com

Owen Jackson@owenjackson.bsky.social · 2y ago

🧵 New research published today by the OECD: 💷 #Cancer adds £14.4bn to annual UK #health expenditure - even accounting for other health costs those who don't get cancer go on to require 📈Without action, per capita costs could increase by >50% by 2050 1/ news.cancerresearchuk.org/2024/11/21/t...

The cost of cancer: what does it mean for the UK’s growth mission - Cancer Research UK - Cancer News

The OECD's report on the economic impact of cancer makes it clear the UK government needs to focus on tackling the disease.

news.cancerresearchuk.org